CELL STATE CORRECTING
LIVE

Serial Number

99215729

Owner

Cellarity, Inc.

Attorney

Christina M. Licursi

Filing Date

Jun 3, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CELL STATE CORRECTING Trademark

Serial Number: 99215729

CELL STATE CORRECTING is a trademark filed by Cellarity, Inc. on June 3, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Cellarity, Inc. (24 trademarks)

Somerville, MA 02143

Entity Type: 03

Trademark Details

Filing Date

June 3, 2025

Registration Date

Not Registered

Goods & Services

Research and development of new products in the nature of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of medicine and diagnostic testing featuring pharmaceutical, therapeutic and biopharmaceutical preparations and agents; pharmaceutical drug development and research; scientific research in the field of drug discovery and development; biomedical research services; pharmaceutical drug development services, namely, preclinical development of therapeutic products; bioinformatic services in the nature of scientific research, namely, collecting and analyzing complex biological data through the use of artificial intelligence; providing temporary use of non-downloadable artificial intelligence (AI) computer software for molecular design in the fields of pharmaceutical research, medicine, and diagnostic testing for disease; scientific diagnostic and screening services for scientific research purposes, namely, conducting scientific diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases; scientific research, namely, research and analysis services in the fields of artificial intelligence and machine learning analytics and research relating to drug development; providing on-line non-downloadable artificial intelligence (AI) software for the capture, collection, conversion, analysis, transmission, processing, receiving, recording, storage and transmission of data, images, information in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable artificial intelligence (AI) software featuring machine learning for data analysis in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable artificial intelligence (AI) software featuring machine learning for drug analysis in drug discovery and development; scientific research, namely, research and analysis services in the scientific fields of artificial intelligence and machine learning analytics, healthcare, biomedical and genomic research; providing on-line non-downloadable artificial intelligence (AI) software featuring machine learning for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks in the field of scientific research; medical research services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases

Pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disorders

Medical diagnostic and screening services in the fields of medicine, diagnostic testing, molecular evaluation, and combating of diseases utilizing artificial intelligence and molecular research

Filing History

NOTIFICATION OF FINAL REFUSAL EMAILED
May 5, 2026 GNFN
FINAL REFUSAL E-MAILED
May 5, 2026 GNFR
FINAL REFUSAL WRITTEN
May 5, 2026 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 14, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 14, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 14, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jan 6, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jan 6, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 15, 2025 GNRN
NON-FINAL ACTION E-MAILED
Oct 15, 2025 GNRT
NON-FINAL ACTION WRITTEN
Oct 15, 2025 CNRT
ASSIGNED TO EXAMINER
Oct 15, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 3, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 3, 2025 NWOS
NEW APPLICATION ENTERED
Jun 3, 2025 NWAP